Wu S - Search Results

1

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.

Wu S, Luo M, To KKW, Zhang J, Su C, Zhang H, An S, Wang F, Chen D, Fu L. Wu S, et al. Mol Cancer. 2021 Jan 18;20(1):17. doi: 10.1186/s12943-021-01307-9. Mol Cancer. 2021. PMID: 33461557 Free PMC article.

2

Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.

Wu S, Fu L. Wu S, et al. Mol Cancer. 2018 Feb 19;17(1):25. doi: 10.1186/s12943-018-0775-3. Mol Cancer. 2018. PMID: 29455646 Free PMC article. Review.

3

Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer.

Luo M, Wang F, Zhang H, To KKW, Wu S, Chen Z, Liang S, Fu L. Luo M, et al. Among authors: wu s. Signal Transduct Target Ther. 2020 Aug 28;5(1):141. doi: 10.1038/s41392-020-0200-4. Signal Transduct Target Ther. 2020. PMID: 32855386 Free PMC article.

4

PBA2, a novel compound, enhances radiosensitivity in various carcinoma cells by activating the p53 pathway in vitro and in vivo.

Liang SB, Wang F, Luo M, Zhang H, Wu SC, Chen Z, Fu LW. Liang SB, et al. Free Radic Biol Med. 2020 Dec;161:224-233. doi: 10.1016/j.freeradbiomed.2020.10.014. Epub 2020 Oct 17. Free Radic Biol Med. 2020. PMID: 33080341 Free article.

5

Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.

Zhang H, Xia Y, Wang F, Luo M, Yang K, Liang S, An S, Wu S, Yang C, Chen D, Xu M, Cai M, To KKW, Fu L. Zhang H, et al. Among authors: wu s. Adv Sci (Weinh). 2021 Mar 24;8(10):2003404. doi: 10.1002/advs.202003404. eCollection 2021 May. Adv Sci (Weinh). 2021. PMID: 34026438 Free PMC article.

6

GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma.

Rong QX, Wang F, Guo ZX, Hu Y, An SN, Luo M, Zhang H, Wu SC, Huang HQ, Fu LW. Rong QX, et al. Mol Cancer. 2021 May 29;20(1):80. doi: 10.1186/s12943-021-01374-y. Mol Cancer. 2021. PMID: 34051805 Free PMC article.

7

PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma.

Luo M, Xia Y, Wang F, Zhang H, Su D, Su C, Yang C, Wu S, An S, Lin S, Fu L. Luo M, et al. Among authors: wu s. Acta Pharm Sin B. 2021 Oct;11(10):3120-3133. doi: 10.1016/j.apsb.2021.03.010. Epub 2021 Mar 9. Acta Pharm Sin B. 2021. PMID: 34729305 Free PMC article.

8

Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo.

Fan Y, Tao T, Guo Z, Wah To KK, Chen D, Wu S, Yang C, Li J, Luo M, Wang F, Fu L. Fan Y, et al. Among authors: wu s. Mol Ther Oncolytics. 2022 Feb 16;24:636-649. doi: 10.1016/j.omto.2022.02.006. eCollection 2022 Mar 17. Mol Ther Oncolytics. 2022. PMID: 35284628 Free PMC article.

9

Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer.

Wang X, Guo Z, Wu X, Chen D, Wang F, Yang L, Luo M, Wu S, Yang C, Huang L, Fu L. Wang X, et al. Among authors: wu x, wu s. Immunotargets Ther. 2023 Jan 4;12:1-16. doi: 10.2147/ITT.S373866. eCollection 2023. Immunotargets Ther. 2023. PMID: 36632330 Free PMC article.

10

A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block "eat-me" signal.

Luo M, Wang X, Wu S, Yang C, Su Q, Huang L, Fu K, An S, Xie F, To KKW, Wang F, Fu L. Luo M, et al. Among authors: wu s. Signal Transduct Target Ther. 2023 Aug 23;8(1):312. doi: 10.1038/s41392-023-01545-x. Signal Transduct Target Ther. 2023. PMID: 37607946 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39,767 results

Search Page

Filters